Porton Advanced's UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File Acceptance
核心洞察
Porton Advanced (搜索)'s umbilical cord-derived mesenchymal stem cell (UC-MSCs) cell bank for exosome (搜索) manufacturing has been accepted by the FDA's CBER under DMF #32973.
The DMF filing enables sponsors to reference the cell bank in their own regulatory submissions, accelerating U.S. FDA review pathways and reducing duplicative documentation.
The company's GMP-compliant exosome (搜索) platform supports multiple cell lines, scales from 2L to 50L bioreactors, and achieves final product concentrations of ≥1E+11 particles/mL.
Porton Advanced (搜索) has announced that its Umbilical Cord-Derived Mesenchymal Stem Cell (UC-MSCs) Cell Bank for exosome (搜索) manufacturing has been accepted for filing by the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research (CBER), under Drug Master File (DMF) #32973. The announcement, made July 8, 2026, marks a significant regulatory milestone for the Cranbury, New Jersey and Suzhou, China-based contract development and manufacturing organization (CDMO).
The DMF acceptance allows sponsors advancing exosome (搜索)-based therapeutic programs to reference DMF #32973 in their own regulatory submissions, including Investigational New Drug (IND) applications and New Drug Applications (NDA). By incorporating a pre-reviewed master file, developers can significantly accelerate FDA review pathways while reducing the burden of duplicative documentation.
"UC-MSCs are among the most clinically validated cell sources for exosome (搜索) production, and securing regulatory acceptance of our cell bank is a critical enabler for our global partners advancing exosome-based programs toward the market," the company stated in its release.
End-to-End Exosome (搜索) Manufacturing Capabilities
Porton Advanced (搜索) has leveraged its GMP-compliant platform, originally built in the cell and gene therapy field, to establish robust manufacturing and quality control systems designed to ensure high purity, high activity, and high stability of exosome (搜索) products.
The platform features flexible cell culture systems supporting multiple cell lines, including HEK293, MSC, K562, and iPSC, enabling sponsors to select the optimal cell source for their specific therapeutic application. Manufacturing processes are scalable from 2-liter to 50-liter bioreactors, facilitating a seamless transition from research and development to commercial production.
Key performance specifications include a final exosome (搜索) product concentration of ≥1E+11 particles/mL and rapid delivery timelines, with GMP-grade exosomes available within one month. The platform also incorporates stringent QC testing covering identity, purity, potency, and safety to ensure batch-to-batch consistency.
Organizational Footprint and Track Record
Porton Advanced (搜索) Solutions, a subsidiary of Porton Pharma Solutions (搜索), operates headquarters in Cranbury, New Jersey, and two GMP sites in Suzhou, China. The company provides end-to-end CDMO solutions for advanced therapy medicinal products (ATMPs), spanning cell banking, process and analytical method development, cGMP production, and fill-and-finish services.
The company's GMP-compliant facilities cover 215,000 square feet and house 10 viral vector GMP-compliant production lines, 12 cell therapy GMP-compliant production suites—including two designated for commercial products—and a multitude of cleanrooms. Porton Advanced (搜索)'s specialized platforms encompass plasmids, viral vectors (lentiviral, adenoviral, AAV), cell therapy CMC services (CAR-T, TCR-T, CAR-NK, HSC, exosome (搜索)), bacterial vectors, and nucleic acid therapies.
To date, Porton Advanced (搜索) has supported clients in securing 26 global IND approvals from the NMPA, FDA, and Medsafe, with 12 ongoing Phase I/II ATMP projects. The company has also facilitated the successful transition of several overseas clinical-stage pipelines into China.
Porton Advanced (搜索) indicated it will continue to advance exosome (搜索) technology applications in drug development and broader regenerative medicine, offering integrated exosome services from raw material customization through formulation development.